English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The aim of this study is to investigate the potential biomarkers associated with chronic myeloid leukemia ( CML ), reveal the metabolite changes related to the continuous phases of tyrosine kinase inhibitors ( TKI s), and find the potential biomarkers associated with treatment effects. Fifty‐two patients with  CML  and 26 matched healthy people were enrolled as the discovery set. Another 194 randomly selected  CML  patients treated with  TKI  were chosen as the external validation set. Plasma samples from the patients and controls were profiled using the gas chromatography‐mass spectrometry‐based metabonomic approach. Multivariate and univariate statistical analyses were combined to select the differential metabolic features. The gas chromatography‐mass spectrometry‐based metabolomics showed a clear clustering and separation of metabolic patterns from healthy controls and pre‐ and post‐ TKI  treatment  CML  patients in the discovery set. We identified 9 metabolites that differentiated  CML  patients from healthy controls, including lactic acid, isoleucine, glycerol, glycine, myristic acid,  d ‐sorbitol,  d ‐galactose,  d ‐glucose, and myo‐inositol. Among the 9 markers, glycerol and myristic acid had the most significant association with  TKI  treatment effects in both discovery and external validation sets. In the receiver operating characteristic analysis, the combination of glycerol and myristic acid showed a better discrimination performance compared to a single biomarker. The results indicated that metabolic profiling has the potential for diagnosis of  CML  and the panel of biomarkers including myristic acid and glycerol could be useful in monitoring  TKI  therapeutic responses.

Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients